Addressing effects of breast cancer among the workforce
Addressing the growing effects of breast cancer among the workforce - Economist Report
Please find attached an Economist Intelligence Unit report on how to address the growing effects of breast cancer among the New Zealand workforce.
In a few weeks time PHARMAC is due to make a decision on funding new treatments which can give New Zealand women with metastatic breast cancer a better quality of life and more time with their loved ones.
has approved the use of Ibrance (palbociclib) for those with
advanced hormone receptor positive and HER2-negative breast
cancer, but it’s only available to those who can pay for
The medicine is a breakthrough drug and preliminary clinical evidence for it was so strong that the United States Food and Drug Administration fast-tracked its use in that country.
Breast Cancer Aotearoa Coalition chairperson Libby Burgess says hundreds of women could potentially benefit from Ibrance now that it is available in New Zealand.
'This medicine is a game changer for women with hormone receptor positive, but HER2- negative breast cancer. It will give them a better quality of life and more time with their loved ones.'
Richard Egan of the University of Otago says 'As cancer has gone from what people used to unfairly think was a death sentence to a chronic disease, we’re starting to think more about survivors, people living well with cancer and past cancer. That change affects individuals, public health and the economy. Survivorship is impacting the rest of society.'
He points out as survival rates improve thanks to earlier detection and improved treatment, there is a need to address the growing effects of breast cancer among the workforce.